PMID: 23949294
Question: Treatment as prevention in resource-limited settings: is it feasible to maintain HIV viral load suppression over time?
Correct Answer: yes

======================= Launch the MCC process =======================
PMID: 23949294
Question: Treatment as prevention in resource-limited settings: is it feasible to maintain HIV viral load suppression over time?

----- GPT's initial response -----
GPT is reasoning the answer...


**1. Question Analysis**
- **Core Content**: The question seeks to determine whether "treatment as prevention" (TasP) strategies can feasibly maintain HIV viral load (VL) suppression over time in resource-limited settings.
- **Key Information to Look For**: Data on viral load suppression rates, duration of treatment, incidence of virologic failure, and any challenges or limitations observed in maintaining suppression over time within the context of resource-limited environments.

**2. Evidence Evaluation**
- **Research Results and Data**:
  - Study conducted in Buenos Aires, Argentina, a resource-limited setting.
  - Among 619 patients, 79 (96.3%) were on HAART with a median therapy duration of 14 years.
  - 87.3% of patients had undetectable VL.
  - 46.8% never experienced virologic failure, and 24.1% experienced only one failure.
  - A small percentage (16.5%) required third-line ART regimens, which were associated with higher rates of virologic failure.
- **Strength and Reliability**:
  - Retrospective observational design provides real-world evidence.
  - A substantial follow-up duration (median of 14 years) strengthens the reliability of long-term suppression data.
- **Relevance**:
  - Directly addresses the feasibility of maintaining VL suppression over time in a resource-limited setting.

**3. Conclusion**
Based on the high rates of undetectable viral loads and the majority of patients maintaining suppression over an extended period, the evidence supports the feasibility of TasP in resource-limited settings despite some challenges related to virologic failure and the need for third-line therapies.

**4. Final Answer**
**My final choice is: "yes"**
GPT selected: yes

----- Qwen's initial response -----
Qwen is reasoning the answer...


**1. Question Analysis**  
The question asks whether maintaining HIV viral load suppression over time is feasible in resource-limited settings through "treatment as prevention" (TasP). Key information to evaluate includes viral load suppression rates, treatment duration, virologic failure rates, and the ability to manage resistance (e.g., third-line ART use) in such settings.  

**2. Evidence Evaluation**  
- **Viral Load Suppression**: Of 82 patients followed for a median of 14 years on HAART, 69 (87.3%) had undetectable viral loads at the study time. This indicates sustained suppression in the majority.  
- **Virologic Failure**: Only 37% never experienced failure, and 24.1% had only one failure, suggesting most maintained suppression eventually.  
- **Third-Line ART**: While 16.5% required third-line regimens (due to multiple failures), this group still represented a minority, and suppression was achievable even after failures.  
- **Conclusion Statement**: The abstract explicitly states, "Maintaining viral load suppression over time in resource-limited settings is feasible," directly aligning with the study’s findings.  

The study’s retrospective design and small sample size (n=82 from pre-HAART era) limit generalizability, but the high suppression rate (87.3%) and explicit conclusion support feasibility.  

**3. Conclusion**  
The data shows that despite challenges like long-term treatment and some virologic failures, the majority of patients maintained viral suppression over 14 years. The study’s conclusion reinforces this, making "yes" the appropriate answer.  

**4. Final Answer:**  
**My final choice is: "yes"**
Qwen selected: yes

----- Deepseek's initial response -----
DeepSeek is reasoning the answer...

**1. Question Analysis**  
The question asks whether maintaining HIV viral load (VL) suppression over time via treatment as prevention (TasP) is feasible in resource-limited settings. Key information to evaluate includes the study's findings on long-term virologic suppression rates, virologic failure frequency, and the need for advanced antiretroviral therapy (ART) regimens, which reflect challenges in sustaining suppression.

**2. Evidence Evaluation**  
The study followed 79 pre-HAART-era patients in Argentina on HAART for a median of 14 years:  
- **87.3% (69/79)** maintained undetectable VL.  
- **46.8% (37/79)** never experienced virologic failure, and **24.1% (19/79)** had only one failure.  
- **16.5% (13/79)** required third-line regimens, which correlated with significantly more failures (p=0.007).  

While third-line use highlights challenges in a subset, the majority achieved long-term suppression. The abstract explicitly concludes feasibility in resource-limited settings. However, the study’s setting (a private center in Buenos Aires) may not fully represent typical resource-limited environments, introducing uncertainty about generalizability.

**3. Conclusion**  
The data strongly supports feasibility for most patients, as the majority maintained suppression over a decade. However, the need for third-line regimens in some cases and potential setting-specific factors (e.g., private clinic access) suggest limitations. The abstract’s direct conclusion aligns with "yes," but contextual uncertainties warrant caution.  

**4. Final Answer**  
**My final choice is: "yes"**
DeepSeek selected: yes

Initial consensus: All models selected yes